Literature DB >> 17579574

2'-O-methyl-modified RNAs act as TLR7 antagonists.

Marjorie Robbins1, Adam Judge, Lisa Liang, Kevin McClintock, Ed Yaworski, Ian MacLachlan.   

Abstract

RNA molecules such as single-stranded RNA (ssRNA) and small interfering RNA (siRNA) duplexes induce Toll-like receptor (TLR)-mediated immune stimulation after intracellular delivery. We have previously shown that selective incorporation of 2'-O-methyl (2'OMe) residues into siRNA abrogates cytokine production without reduction of gene silencing activity. Here we show that 2'OMe-modified RNA acts as a potent inhibitor of RNA-mediated cytokine induction in both human and murine systems. This activity does not require the direct incorporation of 2'OMe nucleotides into the immunostimulatory RNA or that the 2'OMe nucleotide-containing RNA be annealed as a complementary strand to form a duplex. Our results indicate that 2'OMe RNA acts as a potent antagonist of immunostimulatory RNA. We further show that 2'OMe RNA is able significantly to reduce both interferon-alpha (IFN-alpha) and interleukin-6 (IL-6) induction by the small-molecule TLR7 agonist loxoribine in human peripheral blood mononuclear cells (human PBMCs), in murine Flt3L dendritic cells (Flt3L DCs), and in vivo in mice. These results indicate that 2'OMe-modified RNA may have utility as an inhibitor of TLR7 with potential applications in the treatment of inflammatory and autoimmune diseases that involve TLR7-mediated immune stimulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579574     DOI: 10.1038/sj.mt.6300240

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  109 in total

1.  Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice.

Authors:  Sandra M Ocampo; Carolina Romero; Anna Aviñó; Joan Burgueño; Miguel A Gassull; Jordi Bermúdez; Ramon Eritja; Ester Fernandez; Jose C Perales
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

Review 2.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

3.  2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors.

Authors:  Youngju Lee; Johannes H Urban; Li Xu; Bruce A Sullenger; Jaewoo Lee
Journal:  Nucleic Acid Ther       Date:  2016-01-20       Impact factor: 5.486

4.  Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs.

Authors:  Michael A Collingwood; Scott D Rose; Lingyan Huang; Chris Hillier; Mohammad Amarzguioui; Merete T Wiiger; Harris S Soifer; John J Rossi; Mark A Behlke
Journal:  Oligonucleotides       Date:  2008-06

5.  Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses.

Authors:  Sibylle Tluk; Marion Jurk; Alexandra Forsbach; Risini Weeratna; Ulrike Samulowitz; Arthur M Krieg; Stefan Bauer; Jörg Vollmer
Journal:  Int Immunol       Date:  2009-03-30       Impact factor: 4.823

Review 6.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

7.  Production of highly potent recombinant siRNAs in Escherichia coli.

Authors:  Linfeng Huang; Judy Lieberman
Journal:  Nat Protoc       Date:  2013-10-31       Impact factor: 13.491

8.  Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro.

Authors:  Frauke Beilstein; Matthieu Blanchet; Andrew Vaillant; Camille Sureau
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

9.  Base modification strategies to modulate immune stimulation by an siRNA.

Authors:  Rachel Anne P Valenzuela; Scott R Suter; Alexi A Ball-Jones; José M Ibarra-Soza; Yuxuan Zheng; Peter A Beal
Journal:  Chembiochem       Date:  2014-12-08       Impact factor: 3.164

10.  Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis.

Authors:  Virender Kumar; Vinod Kumar; Jiangtao Luo; Ram I Mahato
Journal:  Mol Ther       Date:  2018-09-01       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.